/ /

  • linkedin
  • Increase Font
  • Sharebar

    Retina 2007 (page 5)

    1, 2, 3, 4, 5

    2008: the year for combining approaches?
    So what do our experts think awaits us in 2008? Will we see combination therapy overtake anti-VEGF monotherapy as a treatment of choice in the treatment of AMD? Will we see the launch of even better instrumentation for vitreoretinal surgery? Will the manufacturers of imaging devices surprise us with a more superior technology?

    "Hageman in 2001,3 showed that proteins associated with inflammation and immune-mediated processes are prevalent among drusen-associated constituents and one of the best available markers of AMD risk is single nucleotide polymorphisms in complement factor H (CFH). As such, I hope that next year we will see some research showing that inhibition of complement factors block drusen formation in certain patients," said Dr Mauget-Faysse.


    Professor Rizzo, on the other hand, believes that we will see more and more studies advocating combination approaches to AMD therapy and the treatment of other retinopathies. He also thinks that we will see further improvements to MIVS instrumentation and techniques that allow surgeons to further reduce surgical trauma and increase patient comfort. "I also think that implants, which deliver sustained-release drug therapy for the treatment of DME will continue to yield impressive results in 2008," he hypothesized.

    Dr Stefansson agrees that the benefits of combination therapies and surgery/therapeutic combinations will dominate the headlines in 2008. Meanwhile, he also hopes that studies touting the benefits of retinal oximetry will also be announced next year.

    "I sincerely believe that we will see a shift from 'monotherapeutic thinking' to 'oncologic thinking' in terms of our treatment approaches. I also expect more interest in diabetic retinopathy. Dry AMD and prevention will also be a hot topic," concluded Professor Augustin.

    1. A.J. Augustin, et al. Retina February 2007;27(2):133-140.
    2. M. Inoue, et al. Am. J. Ophthalmol. November 2004;138(5):867-869.
    3. G.S. Hageman et al. Prog. Retina Eye Res. 2001;20:705-732

    Special contributors


    Prof. Dr. Albert L. Augustin             Professor Stanislao Rizzo


    Martine Mauget-Faysse, MD             Einar Stefansson, MD, PhD

    1, 2, 3, 4, 5

    Professor Albert J. Augustin

    Professor Albert J. Augustin, MD is Professor and Chairman of the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, ...

    Martine Mauget-Faysse, MD
    Martine Mauget-Faysse, MD is a retina consultant at the Centre d'Ophtalmologie Rabelais in Lyon, France. She may be reached by E-mail: ...
    Professor Stanislao Rizzo
    Professor Stanislao Rizzo, MD is Chief of the Eye Surgery Clinic at Santa Chiara Hospital, Azienda Ospedaliero-Universitaria ...
    Fedra Pavlou
    Fedra Pavlou is the Editor-in-Chief of Ophthalmology Times Europe. She may be reached by Tel: +44 (0)1244 393 420 or E-mail:
    Professor Einar Stefansson
    Einar Stefánsson MD PhD is Professor of Ophthalmology and Faculty Chair at the Department of Ophthalmology, University of Iceland, ...

    New Call-to-action


    View Results